Below is a series of media releases and media statements from Hepatitis Australia.
Media outlets wishing to arrange interviews should contact our office on 02 6232 4257 or send an email.
The latest data relating to hepatitis B or C is available on our Hepatitis Statistics page.
The World Hepatitis Summit 2022 will review progress and renew commitments by global partners to accelerate action to achieve the global target of eliminating of viral hepatitis by 2030. Read more
Hepatitis Australia welcomes the Australian Government’s commitment of short-term (12 months) funding under the National Preventive Health Strategy 2021-2030 to support key organisations to continue existing programs in the national response to hepatitis B, hepatitis C, HIV and STIs. Read more
Media Statement Budget 2021: Hepatitis Australia welcomes the Australian Government’s commitment to extend telehealth and remove access barriers in the 2021 Budget. Patients with hepatitis B and hepatitis C can now access treatment via telehealth without needing to have previously or recently seen that clinician. Read more
Media statement Budget 2021: Hepatitis Australia welcomes the Australian Government’s significant investment of $6.7 billion in medical research over the next 4 years, including $2.6 billion for the Medical Research Future Fund (MRFF) and $3.6 billion for the National Health and Medical Research Council (NHMRC). Read more
The Australian Injecting and Illicit Drug Users League (AIVL) and Hepatitis Australia are highlighting international calls for Needle and Syringe Programs (NSPs) in prisons, along with a greater focus on harm reduction initiatives, ahead of International Drug Users Day on 1 November. Read more
6 October 2020 - Hepatitis Australia welcomes the Australian Government’s commitment to diverse hepatitis research, however we remain concerned that the 2019 Health Budget funding for hepatitis commitments is yet to hit the ground. Read more
6 October 2020 - Hepatitis Australia welcomes the Australian Government’s significant investment of $230 million to expand the listing of Tecentriq® and Avastin® (atezolizumab and bevacizumab) on the Pharmaceutical Benefits Scheme (PBS). Read more
6 October 2020 - Hepatitis Australia is celebrating the news that the Nobel Prize in Physiology or Medicine 2020 has been awarded jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice ‘for the discovery of Hepatitis C virus’. Read more
As Australia grapples with COVID-19 outbreaks, it is important to remember that viral hepatitis is also a pandemic. Viral hepatitis can lead to liver cancer and directly impacts nearly 360,000 people in Australia. Read more
04 March 2020 - Hepatitis Australia announces appointment of new CEO Read more
17 January 2020 - Hepatitis Australia announces Grant Phelps as the new President of the Board. Read more
Welcome to our newly updated website. The fresh new look is easier to navigate, so finding information about hepatitis or how to get help is even simpler. Read about the new features and how to leave feedback here. Read more
The latest hepatitis C treatment data released by the Kirby Institute shows that, since March 2016, an estimated 70,260 people in Australia have commenced treatment to cure hepatitis C*. But is this enough to prevent the ongoing deaths each year in Australia from liver disease associated with hepatitis? Read more
In England deaths from liver disease related to hepatitis C fell by more than 16% between 2015 and 2017, achieving the World Health Organization’s (WHO’s) target to reduce HCV-related mortality by 10% by 2020 three years early. Australia has also achieved the WHO’s 2020 mortality target. Some might say that this is good news - but at Hepatitis Australia we don’t agree. Read more
Hepatitis Australia is pleased to have received full support from The Australian Greens for our call to address gaps in hepatitis treatment and care. Read more